DOAJ Open Access 2025

Global frequency, diagnosis, and treatment of hereditary angioedema with normal C1 inhibitor

Markus Magerl, MD Marc A. Riedl, MD, MS Luisa Karla Arruda, MD, PhD Andrea Bauer, MD, MPH Alejandro Berardi, MD +30 lainnya

Lihat Sumber DOI

Abstrak

Background: Hereditary angioedema (HAE) is a rare genetic disease, most frequently associated with deficiency or dysfunction in the C1 inhibitor protein. HAE with normal C1 inhibitor (HAE-nC1INH) lacks standardized diagnostic tests, limiting precise prevalence estimates and development of specific treatment guidelines. Objective: This study sought to describe the global frequency, diagnostic pathway, and current treatment patterns of HAE-nC1INH. Methods: Board-certified HAE-treating physicians from accredited Angioedema Centers of Reference and Excellence (ACAREs) were invited to complete a 27-item online survey between December 2022 and April 2023. Results: Thirty physicians from 30 ACAREs across 15 countries reported a mean of 71 (range, 11-148) patients with HAE assessed/treated within the previous 12 months. On average, physicians estimated 24% (range, 2-44%) of patients with HAE were diagnosed with HAE-nC1INH, most of whom were adults (88%). To diagnose HAE-nC1INH, physicians most commonly assessed family history and plasma C4 levels (90% each), and C1 function and quantitative levels (87% each). On-demand and prophylactic treatment patterns varied widely across countries, with an average (range) of 56% (33-100%) of patients receiving on-demand treatment only, and 37% (0-67%) receiving both on-demand and prophylactic treatment. Physicians identified the greatest unmet needs in HAE-nC1INH management as treatment specifically indicated for this patient population and availability of an oral treatment. Conclusion: HAE-nC1INH may be more prevalent than previously reported. Importantly, our findings revealed varying diagnostic and treatment approaches. Validated, accessible diagnostic biomarkers and clinical outcomes derived from rigorous clinical trials assessing mechanistically based treatments would advance understanding and management of HAE-nC1INH.

Topik & Kata Kunci

Immunologic diseases. Allergy

Penulis (35)

Markus Magerl, MD

Marc A. Riedl, MD, MS

Luisa Karla Arruda, MD, PhD

Andrea Bauer, MD, MPH

Alejandro Berardi, MD

Jonathan A. Bernstein, MD

Laurence Bouillet, MD, PhD

Matthew Buckland, PhD

Thomas Buttgereit, MD

Danny M. Cohn, MD, PhD

Timothy Craig, DO

Roberta F. Criado, MD, PhD

Aurélie Du-Thanh, MD, PhD

Olivier Fain, MD

Margarida Gonçalo, MD, PhD

Jens Greve, MD

Anete Sevciovic Grumach, MD, PhD

Mar Guilarte, MD, PhD

Constance Katelaris, MD, PhD

Tamar Kinaciyan, MD

Elena A. Latysheva, MD

Ramon Lleonart, MD

Oscar Calderón Llosa, MD

Eli Mansour, MD, PhD

Vesna Grivcheva-Panovska, MD, PhD

Claudio Parisi, MD

Nelson Augusto Rosario Filho, MD, PhD

Amélia Spínola Santos, MD

Petra Staubach, MD

Anna Valerieva, MD, PhD

Solange Oliveira Rodrigues Valle, MD, PhD

Sherry Danese, MBA

Julie Ulloa

Paul K. Audhya, MD, MBA

Marcus Maurer, MD

Format Sitasi

APA MLA BibTeX

MD, M.M., MS, M.A.R.M., PhD, L.K.A.M., MPH, A.B.M., MD, A.B., MD, J.A.B. et al. (2025). Global frequency, diagnosis, and treatment of hereditary angioedema with normal C1 inhibitor. https://doi.org/10.1016/j.jacig.2025.100446

Akses Cepat

PDF tidak tersedia langsung

Cek di sumber asli →

Lihat di Sumber doi.org/10.1016/j.jacig.2025.100446

Informasi Jurnal

Tahun Terbit: 2025
Sumber Database: DOAJ
DOI: 10.1016/j.jacig.2025.100446
Akses: Open Access ✓